Sesquiterpenes from the Saudi Arabian Red Sea sponge Lamellodysidea herbacea

IF 1.3 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2025-05-01 DOI:10.1016/j.phytol.2025.102969

Mohamed A. Tammam , Leto-Aikaterini Tziveleka , Carlos M. Duarte , Efstathia Ioannou , Vassilios Roussis

引用次数: 0

Abstract

Eleven sesquiterpenes (1–11), with the majority of them decorated with either a furan or a γ-lactone moiety in their carbocycle, were isolated from an organic extract of the marine sponge Lamellodysidea herbacea collected from the coral reefs in the vicinity of Thuwal in Saudi Arabia. Two of the isolated metabolites (1 and 2) are not previously described, whereas the linear furanosesquiterpene 11 is reported for the first time from a natural source. The structures and the relative configurations of the isolated metabolites have been determined through extensive analysis of their NMR and MS data. Compounds 1–11 were evaluated for their antibacterial and antioxidant activity but did not display any noteworthy activity.

查看原文本刊更多论文

沙特阿拉伯红海海绵的倍半萜素

从沙乌地阿拉伯图瓦尔附近珊瑚礁的海绵lamellodysida herbacea有机提取物中分离出11个倍半萜（1-11），其中大部分在其碳环中带有呋喃或γ-内酯基团。两个分离的代谢物（1和2）以前没有描述过，而线性呋喃半萜烯11是第一次从自然来源报道。通过对其核磁共振和质谱数据的广泛分析，确定了分离代谢物的结构和相对构型。化合物1-11的抗菌和抗氧化活性被评价，但没有显示出明显的活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.